|
시장보고서
상품코드
2051372
원료의약품 시장 : 제품 유형별, 분자 유형별, 제형별, 용도별, 지역별Active Pharmaceutical Ingredients Market, By Product Type, By Molecular Type, By Formulation, By Application, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
원료의약품(API) 시장은 2026년에 2,868억 1,000만 달러로 추정되며, 2033년까지 4,605억 6,000만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 7.0%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 2,868억 1,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.00% | 2033년 시장 규모 예측: | 4,605억 6,000만 달러 |
원료의약품(API)과 첨가제는 의약품 제조에 있어 가장 중요한 두 가지 구성요소입니다. API는 의약품 제조에 사용되는 원료이며, 첨가제는 정제에 포함된 유당이나 미네랄 오일 등 체내 약물 흡수를 돕는 매개체 역할을 하는 물질입니다. 의약품 원료의약품은 연구개발 단계와 상업적 생산 단계 모두에서 고도의 기술력이 요구되는 산업 공정을 통해 제조됩니다. 이러한 화합물은 약리작용을 발휘하거나 질병의 진단, 치료, 완화, 완화, 치료, 예방에 직접적인 영향을 미치거나 신체의 구조와 기능을 변화시키는 것을 목적으로 개발됩니다. 활성 제약 성분(API) 시장의 성장은 각 지역 정부의 자금 지원 이니셔티브 증가와 같은 특정 요인에 기인하는 것으로 추정됩니다. 예를 들어, 2021년 5월 미국 보건복지부(HHS)는 제약회사 Phlow Corporation에 COVID-19 및 관련 질환 환자 치료를 위한 의약품에 필요한 원료의약품(API)을 제조하는 4년간의 계약에 따라 3억 5,400만 달러의 자금을 지원한다고 발표했습니다.
시장 역학
미국 식품의약국(FDA)의 의약품 승인 건수 증가는 예측 기간 동안 세계 원료의약품(API) 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 예를 들어, 2021년 12월 일라이 릴리는 제2형 당뇨병 치료제 트루리시티(Trulicity)의 증량 투여, 전이성 추정 사구체여과율(eGFR) 돌연변이 양성 비소세포폐암 치료제 사이람자(Cyramza), 알츠하이머병 환자를 위한 타우비드(Tauvid) 등 여러 의약품에 대해 미국 FDA의 승인을 받았습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 본 보고서에서는 세계 원료의약품(API) 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등 다양한 매개 변수를 기반으로 분석하여 소개합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 원료의약품(API) 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 원료의약품(API) 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 원료의약품 시장 : 제품 유형별, 2026-2033년
제5장 세계의 원료의약품 시장 : 분자 유형별, 2026-2033년
제6장 세계의 원료의약품 시장 : 제제별, 2026-2033년
제7장 세계의 원료의약품 시장 : 용도별, 2026-2033년
제8장 세계의 원료의약품 시장 : 지역별, 2026-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.06.16Active Pharmaceutical Ingredients Market is estimated to be valued at USD 286.81 Bn in 2026 and is expected to reach USD 460.56 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 286.81 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 460.56 Bn |
Active pharmaceutical ingredients (APIs) and excipients are the two most important components in the production of a medication. API is the raw material, which is used in manufacturing medications, whereas excipient is a substance that functions as a medium to help the body absorb the drug such as lactose or mineral oil in a tablet. Active pharmaceutical ingredients are produced by using highly technological industrial processes, both during the research & development and commercial production phases. Such compounds are developed to provide pharmacological activity or other direct impacts on disease diagnosis, cure, mitigation, therapy, or prevention, or to change the structure and function of the body. The growth of active pharmaceutical ingredient (API) market can be attributed to certain factors such as increasing funding initiatives by the government across different regions. For instance, in May 2021, the U.S. Department of Health and Human Services (HHS) announced that it will provide a funding of US$ 354 million to Phlow Corporation, a pharmaceutical company, under a four-year contract to produce the active pharmaceutical ingredients (APIs) needed for medications to treat patients with COVID-19 and related illnesses.
Market Dynamics
The rising U.S Food & Drug Administration (FDA) approvals for drugs by pharmaceutical companies is further expected to boost the global active pharmaceutical ingredient (API) market growth during the forecast period. For instance, in December 2021, Eily Lilly received the U.S FDA clearance for several medicines including increased dosages of its Trulicity therapy for the treatment of type 2 diabetes, Cyramza for the treatment of metastatic Estimated Glomerular Filteration Rate (EGFR)-mutated non-small cell lung cancer, and tauvid for individuals diagnosed with Alzheimer's disease.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global active pharmaceutical ingredient (API) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG, and Biological E. Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global active pharmaceutical ingredient (API) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global active pharmaceutical ingredient (API) market
Market Segmentation
- Global Active Pharmaceutical Ingredient (API) Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
- Low Potent APIs
- High Potent APIs
- Global Active Pharmaceutical Ingredient (API) Market, By Molecular Type (Revenue, USD Bn, 2021 - 2033)
- Small Molecules
- Large Molecules
- Global Active Pharmaceutical Ingredient (API) Market, By Formulation (Revenue, USD Bn, 2021 - 2033)
- Oral
- Topical
- Injectable
- Drops
- Global Active Pharmaceutical Ingredient (API) Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- Global Active Pharmaceutical Ingredient (API) Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Reddy's Laboratories Ltd.
- Novartis AG
- Mylan N.V.
- Amneal Pharmaceuticals LLC
- Lonza Group
- Lupin Limited
- Fresenius Kabi
- Hikma Pharmaceuticals
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Endo International plc
- Aurobindo Pharma Limited
- Apotex Inc
- Taro Pharmaceutical Industries Ltd
- Stada Arzneimittel AG
- Krka Pharmaceuticals
- CordenPharma International
- Evonik Industries AG
- Biological E. Limited.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Molecular Type
- Market Snippet, By Formulation
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- API Patent Expiration
- Production Capability Analysis
- Mergers, Acquisitions and Collaboration Scenario
- Key Developments
- PEST Analysis
- Investments & Funding
- Production and Consumption Analysis
4. Global Active Pharmaceutical Ingredients (API) Market, By Product Type, 2026 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Low Potent APIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- High Potent APIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
5. Global Active Pharmaceutical Ingredients (API) Market, By Molecular Type, 2026 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Large Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
6. Global Active Pharmaceutical Ingredients (API) Market, By Formulation, 2026 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Injectables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
7. Global Active Pharmaceutical Ingredients (API) Market, By Application, 2026 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Cardiovascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- CNS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Ophthalmic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Respiratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Dermatology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Bn)
8. Global Active Pharmaceutical Ingredients (API) Market, By Region, 2026 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2026 -2033, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2026 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2026 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2026 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2026 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Product Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Molecular Type, 2026 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Formulation, 2026-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2026-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2026 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Dr. Reddy's Laboratories Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Amneal Pharmaceuticals LLC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Lonza Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Lupin Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hikma Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Endo International plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Aurobindo Pharma Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Apotex Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Taro Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Stada Arzneimittel AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Krka Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- CordenPharma International
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Evonik Industries AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biological E. Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd
10. Section
- References
- Research Methodology
- About us and Sales Contact
